Free Essay

How I Treat Eatl

In: Science

Submitted By etmberi2001
Words 9183
Pages 37
From www.bloodjournal.org by guest on March 10, 2015. For personal use only.

How I treat

How I treat enteropathy-associated T-cell lymphoma
Antonio Di Sabatino,1 Federico Biagi,1 Paolo G. Gobbi,1 and Gino R. Corazza1
1First Department of Medicine, Centro per lo Studio e la Cura della Malattia Celiaca, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, University of Pavia, Pavia, Italy

Enteropathy-associated T-cell lymphoma (EATL) is a complication of celiac disease (CD). This tumor derives from the neoplastic transformation of aberrant intraepithelial T lymphocytes emerging in celiac patients unresponsive to a gluten-free diet. Poor adherence to a gluten-free diet, HLA-DQ2 homozygosity, and late diagnosis of CD are recognized as risk factors

for malignant evolution of CD. Recurrence of diarrhea, unexplained weight loss, abdominal pain, fever, and night sweating should alert physicians to this complication. The suspicion of EATL should lead to an extensive diagnostic workup in which magnetic resonance enteroclysis, positron emission tomography scan, and histologic identification of

lesions represent the best options. Treatment includes high-dose chemotherapy preceded by surgical resection and followed by autologous stem cell transplantation, although biologic therapies seem to be promising. Strict adherence to a gluten-free diet remains the only way to prevent EATL. (Blood. 2012;119(11): 2458-2468)

Introduction
Celiac disease (CD) is a chronic gluten-sensitive enteropathy characterized by a high prevalence in the general population and an increased mortality.1,2 It is well known that the increased mortality is mainly the result of the complications of CD itself, represented by refractory CD (RCD) and enteropathy-associated T-cell lymphoma (EATL).2 RCD is a form of CD that does not respond histologically to at least 12 months of a strict gluten-free diet (GFD).3 RCD can also evolve in patients who initially responded normally to a GFD and who are still maintaining a strict GFD. On the basis of the intraepithelial lymphocyte (IEL) population, RCD is further classified into type 1 and type 2. RCD type 1 (RCD1) is characterized by persisting villous atrophy despite a strict GFD associated with increased but still phenotypically normal IELs. Conversely, a clonal expansion of abnormal IELs lacking surface CD3, CD8, and T-cell receptor (TCR) markers but expressing intracellular CD3 indicates RCD type 2 (RCD2), a condition that frequently evolves into EATL, the most serious complication of CD.4 In the past, up to 20% of celiac patients were considered to be affected by a nonresponsive form of CD. This was obviously because of the lack of consensus on the definition of nonresponsiveness.4 In the last few years, some evidence has suggested that the prevalence of RCD is low, ranging from 0.6% to 1.5%.3,5,6 Although the presence of RCD in CD is probably to be approximately 1%, the prevalence of RCD2 among patients with RCD is far from being ascertained. Probably because of not only the great differences in the diagnostic criteria,4 but also referral bias, different papers report very different results, which vary from 15% to 75%.7-9 Finally, although the incidence of EATL was reported to be rare in the general population (1 per million person-years),10,11 it was shown that it occurs in 60% to 80% of patients with RCD2 within 5 years.7-9,12 The description of EATL arising in patients with RCD1 seems to be exceptional.7 Recent evidence suggests that non-EATLs, including intestinal B-cell and extraintestinal T-cell lymphomas, may rarely occur in celiac patients.13,14 As far as the prognosis of all these conditions is concerned, there are no doubts that it is much worse than that of uncomplicated CD.2,15 The 5-year survival rate is reported to be between 80% and 96% in patients with RCD1, but it is only between 40% and 58% in patients with RCD2.6-8,15 Five-year survival dropped to between 8% and 20% in RCD2 patients who developed EATL.8,9,16

Natural history
The first paper suggesting that CD predisposes to intestinal lymphoma was published 50 years ago,17 and 5 years ago it was shown that EATL is strongly linked to CD.18 In the last few years, it has emerged that several factors increase the risk of developing malignant complications in patients with CD. This is the case for not only poor adherence to a GFD but also advanced age at diagnosis ( 50 years), diagnostic delay for CD ( 10 years), and HLA-DQ2 homozygosity.2,19 Moreover, we have recently hypothesized that the total amount of gluten consumed not only after but also before the start of a GFD could play a role in inducing celiac complications.2 It should, however, be noted that most of the evidence supporting a protective effect of a GFD is indirect and that studies directly testing this hypothesis are scarce. Hence, it follows that this is an area that needs further study with regard to subgroups of CD patients and subgroups of lymphoma. Although some celiac patients complicating directly into EATL have been described,12 most of the time celiac complications arise as either RCD1 or RCD2. Some patients can also develop ulcerative jejunoileitis (UJI), a premalignant small bowel disorder that shares many immunopathologic features with RCD2 and is characterized by multiple ulcerations evolving in strictures of the intestinal wall.20,21 Both RCD2 and UJI can subsequently degenerate into EATL20,21 through a progressive accumulation in the intestinal epithelium of aberrant (CD3 , CD103 , CD8 , CD4 , TCR) and clonal (restricted rearrangements of TCR- chain)

Submitted October 12, 2011; accepted January 17, 2012. Prepublished online as Blood First Edition paper, January 23, 2012; DOI 10.1182/blood-2011-10385559.

© 2012 by The American Society of Hematology

2458

BLOOD, 15 MARCH 2012 VOLUME 119, NUMBER 11

From www.bloodjournal.org by guest on March 10, 2015. For personal use only.
BLOOD, 15 MARCH 2012 VOLUME 119, NUMBER 11 ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA 2459

Figure 1. Schematic representation of IL-15 lymphomagenic action leading to the emergence of EATL in CD. In active CD mucosa, IL-15, mainly produced by epithelial cells and dendritic cells (DCs), which present tissue transglutaminase (tTG)–deamidated gluten peptides to T cells in the context of HLA-DQ2 or HLA-DQ8 molecules, promotes the IEL cytotoxicity against epithelial cells by activating the perforin/granzyme system and favoring the interaction between the homodimeric NK activating receptor NFG2D and the major histocompatibility complex class I–related ligands (MIC), thus leading to enterocyte apoptosis. In addition, IL-15 inhibits IEL apoptosis, thus favoring the emergence of neoplastic IEL clonal proliferations, leading to the development of EATL. Activated gluten-reactive T helper cell type 1 cells (Th1) produce high levels of the proinflammatory cytokine IFN- , which contributes to the mucosal damage by further activating the cytotoxicity of IELs against enterocytes.

IELs,22 abnormally expanded by the antiapoptotic action of IL-15 (Figure 1).23,24 As far as we know, it is not clear whether RCD1 and RCD2 are 2 different phases of the same condition or 2 independent conditions. Because a progression of RCD1 into RCD2 has been described in only 2 patients9 and EATL has been described in only 2 patients with RCD1,7 RCD1 and RCD2 may be 2 unrelated conditions.

Diagnosis
Clinical presentation

EATL manifests in adult patients with previously diagnosed CD, successfully treated until then with a strict GFD (secondary EATL), as an exacerbation of the classic symptoms of CD, such as abdominal pain, diarrhea, and unexplained weight loss.1 The concomitant presence of fever and night sweating, together with laboratory parameters indicative for hypoalbuminemia, anemia, and increased lactate dehydrogenase (LDH), should alert physicians to this complication. The median age at diagnosis of EATL is 60 years, with similar frequency between men and women. On the other hand, EATL may also arise in patients without a known history of CD and on a gluten-containing diet (primary EATL), and in these cases the diagnosis is more difficult and delayed because of the low specificity of symptoms and a very low index of clinical suspicion.16 In the subjects with EATL identified before CD has been diagnosed, the link between CD and EATL may be suggested by the detection of CD-specific antibodies (either antiendomysial or antitransglutaminase), although the latter often disappear once the refractory state is fully developed.7,15 Because EATL may be complicated by gastrointestinal perforation, obstruction, or hemorrhage, many EATLs are diagnosed at laparotomy. At gross examination, EATL appears as a massive tumor infiltration, which may be transparietal, with ulcerations and induration of the intestinal wall. Up to 25% of cases have a

multifocal presentation, and the proximal small bowel, particularly the jejunum, is a more common localization than the large bowel or rectum.25 There are reports of an association between EATL and peripheral eosinophilia,26 mesenteric lymph node cavitation,27 or splenic atrophy,28 the latter of which may increase susceptibility to severe infections or sepsis.29 Malnutrition is a common feature, especially when EATL has an insidious and chronic presentation or manifests after a long-standing RCD.16 Extraintestinal presentation of EATL is rare, and there is a lack of data on the precise characteristics of its cutaneous, neuromeningeal, or pulmonary manifestations. Systemic or B symptoms,30 such as fever of no evident cause, night sweats, and weight loss of more than 10% of body weight, should be taken as signs of clinical progression, although they occur in less than 30% of EATLs.16,31 A high level of clinical suspicion for an overt lymphoma should lead to an extensive workup, including abdominal imaging, endoscopy, and histologic examination of gut biopsies (Figure 2). Laparotomy with collection of full-thickness biopsy specimens may be necessary in some cases.
Staging

Staging procedures as recommended for lymphoma, such as bone marrow examination, CT scan of the thorax, and sonography of the neck, are required for therapeutic decision-making. However, classic lymphoma staging systems32,33 have failed in providing adequate prognostic treatment guidance in patients with EATL. The Lugano system30 is the staging method commonly used for intestinal lymphoma, although its prognostic value in EATL is uncertain. The Prognostic Index for Peripheral T-Cell Lymphoma34 was more predictive of survival than the International Prognostic Index,33 as 3 of the 5 components of the latter (ie, tumor stage, age, and number of extranodal sites) were irrelevant for EATL prognosis. Conversely, risk factors identified through the Prognostic Index for Peripheral T-Cell Lymphoma (ie, tumor size 5 cm, nonambulatory performance status, and raised C-reactive protein and LDH levels) were found to be significantly associated with a worse

From www.bloodjournal.org by guest on March 10, 2015. For personal use only.
2460 DI SABATINO et al BLOOD, 15 MARCH 2012 VOLUME 119, NUMBER 11

Figure 2. Proposed diagnostic algorithm in EATL. The recurrence of celiac symptoms in a patient with CD under GFD, or the persistence of celiac symptoms in a recently diagnosed CD patient despite a GFD followed for more than 12 months, should raise the suspicion of RCD. In that case, the compliance to GFD should be ascertained, and, if sufficient, patients should undergo upper endoscopy with collection of duodenal biopsies. A rate of more than 20% of aberrant IELs, assessed by flow cytometric analysis of freshly isolated cells, points toward a diagnosis of RCD2. In that case, EATL should be excluded through both imaging (either MR enteroclysis or CT scan together with PET scan) and double-balloon endoscopy with collection of small bowel biopsies. The occurrence of celiac and B symptoms (fever of no evident cause, night sweats, and weight loss of 10% of body weight) in a patient without a known history of CD and on gluten-containing diet (primary EATL) or the co-occurrence of B symptoms and cachexia in the 2 aforementioned patient subsets suspected to be refractory (secondary EATL) should raise the suspicion of EATL. In that case, patients should undergo both upper endoscopy and double-balloon enteroscopy with collection of small bowel biopsies and imaging procedures (either MR enteroclysis or CT scan together with PET scan). In the case of EATL confirmation, a staging should be performed through bone marrow examination, CT scan of the thorax, and sonography of the neck.

From www.bloodjournal.org by guest on March 10, 2015. For personal use only.
BLOOD, 15 MARCH 2012 VOLUME 119, NUMBER 11 ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA 2461

Figure 3. Features of EATL at PET scan. Intensely increased 18F-FDG-PET uptake areas (arrows) are evident on axial, sagittal, and coronal images of the small bowel of a patient with EATL.

overall survival and failure-free survival in patients with EATL.34 A preliminary report35 identified 3 risk factors predictive for survival in a multivariate analysis (ie, raised LDH, presence of Bsymptoms, and secondary EATL). This new prognostic model showed superior predictive capacity compared with the International Prognostic Index and made it possible to identify a high-risk group needing more aggressive therapies. It must be stressed, however, that all these prognostic studies were performed on patient series, which were either very heterogeneous or very small, besides being treated without intensified chemotherapy, and in a pre-autologous hematopoietic stem cell transplantation era. Thus, they can be of little help in selecting modern treatments.
Imaging and endoscopy

diagnostic accuracy of MR enteroclysis in detecting RCD2 or EATL was estimated to be almost 90%.42 Diagnostic accuracy can be further improved by wireless capsule endoscopy, which makes it possible to assess the extent of small bowel involvement and the presence of ulcerations, and is also a well-tolerated procedure, although contraindicated in case of suspected strictures.43 Double-balloon enteroscopy may allow a definitive diagnosis of EATL thanks to the collection of biopsy specimens.44 A recent study45 has shown that double-balloon enteroscopy is able to identify even diminutive small bowel lesions (ie, multiple polyps, fine granular mucosa, and swollen folds), thus suggesting a promising role for this technique in diagnosing EATL at an early stage.
Pathology

Although new imaging (MR enteroclysis, PET scan) and endoscopic techniques (wireless capsule endoscopy, double-balloon enteroscopy) able to visualize the entire small bowel are currently available,36 the exact diagnostic algorithm in EATL is still unclear because of the lack of studies aimed at comparing the accuracy of the different diagnostic modalities.37 Abdominal CT scan has a higher accuracy than small bowel enema in detecting EATL, which appears as a thickened small bowel loop with possible signs of mucosal ulcerations. Moreover, CT scan permits the visualization of extraintestinal findings, and it was proposed that the detection of bowel wall thickening, mesenteric lymph node cavitation, intussusception, and small-sized spleen ( 120 cm3) should raise suspicion for RCD2 or EATL.38 PET scan has a high sensitivity in detecting EATL (Figure 3),39 but active peristalsis and inflammation may affect its specificity.40 MR imaging is particularly useful in detecting EATL confined to the epithelial layer of the bowel wall or multifocal, and in assessing the response to treatment.41 The

Histologic examination of small intestinal biopsies remains crucial in the diagnostic workup of EATL. Two different types of EATL are recognized on the basis of the specific immunophenotype: EATL type 1, which is characterized by CD56 negativity; and EATL type 2, which shows CD56 expression.18 EATL type 1, which is more frequent than EATL type 2 and is the only one associated with CD, is composed of CD3 ,CD4 , CD8 ,CD5 , CD7 ,CD103 ,CD56 ,TCR / cells, which mostly express CD30. The cytotoxic phenotype of EATL type 1 cells, which are perforin , granzyme B , and TIA-1 , reflects the origin of the tumor from cytotoxic IELs.46,47 EATL type 1 mostly consists of medium-sized to large tumor cells with round or angulated vesicular nuclei, prominent nucleoli, and pale-staining cytoplasm and an increased mitotic index, often associated with a moderate to abundant infiltrate of eosinophils, histiocytes, and small lymphocytes (Figure 4A-C).25 The neighboring mucosa shows histologic features of active CD, such as

From www.bloodjournal.org by guest on March 10, 2015. For personal use only.
2462 DI SABATINO et al BLOOD, 15 MARCH 2012 VOLUME 119, NUMBER 11

Figure 4. Histologic features of EATL. Medium-sized to large tumor cells with hyperchromatic nuclei, prominent nucleoli, and moderate to abundant, pale-staining cytoplasm, intermingled with eosinophils, are evident in the small bowel tissue specimen of a patient with EATL (A: H&E stain, original magnification 100). The lesion is characterized by a considerable proportion of CD3-positive cells (B: CD3 immunostain, original magnification 40) and a high proliferative rate (C: Ki-67 immunostain, original magnification 40). At a lower magnification (D: H&E stain, original magnification 20), it can be seen that the mucosa adjacent to the tumor shows histologic features of active CD, such as crypt hyperplasia, increased IEL infiltration, and villous atrophy.

crypt hyperplasia, increased IEL infiltration, and villous atrophy (Figure 4D). EATL type 2 is characterized by a monomorphic infiltrate of small- to medium-sized CD3 ,CD4 , CD8 , CD56 , TCR cells. CD30 is often negative in EATL type 2, and the CD56 positivity suggests that a different mechanism underlies the lymphomagenic process of this tumor, which indeed is less commonly associated with CD.18 A PCR analysis indicative for a monoclonal rearrangement of the TCR- chain on intestinal tissue sections and an immunohistochemical or flow cytometric characterization of IELs indicative for an aberrant T-cell population have a high predictive value in identifying the progression of RCD into EATL48 and therefore can be of help in the diagnostic workup before an overt lymphoma has developed. Among the methods used to detect monoclonal rearrangement of TCR- genes, PCR has the advantage that it can be applied to formalin-fixed, paraffin-embedded specimens,49 unlike Southern blotting on extracted DNA, which requires fresh frozen tissue.50 TCR- clonal amplification has been identified in the duodenal biopsies of patients with RCD2 and UJI as in the subsequent tumor specimens.51,52 These findings further strengthen the concept that RCD2 and UJI can be regarded as “cryptic lymphomas” and should encourage performing an extensive diag-

nostic workup to exclude an overt lymphoma in both these premalignant conditions. As far as the analysis of IEL phenotype is concerned, it has been shown that immunohistochemistry allows the discrimination between uncomplicated CD and RCD through the identification in the latter of aberrant IELs expressing a cytoplasmic CD3 chain but lacking CD3 and CD8 surface expression.53 However, flow cytometric analysis of IELs freshly isolated from intestinal biopsy specimens and permeabilized for CD3 cytoplasmic staining seems to be preferable to immunohistochemistry in the discrimination of RCD1 and RCD2 according to the cut-off value of 20% aberrant IELs (cytoplasmic CD3 , surface CD3 , CD7 , CD103 , CD8 , CD4 ) proposed by Verbeek et al,48 although this technique is available only in tertiary referral centers. The main clinical, laboratory, and pathologic parameters, which guide us in the diagnostic management of patients with EATL, are summarized in Table 1.

Genetics
Homozygosity for HLA-DQ2 (HLA-DB1*02) and allelic variants of the MYO9B gene region have been found to be associated with

From www.bloodjournal.org by guest on March 10, 2015. For personal use only.
BLOOD, 15 MARCH 2012 VOLUME 119, NUMBER 11 ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA 2463

Table 1. Clinical, laboratory, and pathology findings in EATL
Intestinal symptoms Abdominal pain Diarrhea Systemic or B symptoms Fever Night sweating Unexplained weight loss Gastrointestinal complications Perforation Obstruction Hemorrhage Comorbidity Splenic hypofunction/atrophy Mesenteric lymph node cavitation Severe malnutrition Laboratory findings Anemia Peripheral eosinophilia Low albumin High lactate dehydrogenase Pathology findings CD3 positivity/CD4 negativity High mitotic index Nonmonomorphic infiltrate CD56 negativity CD30 positivity High eosinophils, histiocytes, and small lymphocytes Monoclonal rearrangement of the TCR- chain at PCR analysis

hemorrhage or perforation, which might become higher during chemotherapy or radiotherapy. A complication often represents the revealing event of the underlying lymphoma, and the consequent emergency surgery also has an important diagnostic role.31 A possible drawback of intestinal surgery has been indicated in the delayed start of chemotherapy, especially when postoperative fistulas or infections or problems of wound healing occur. Data from reports on single cases or a few patients would suggest a better prognosis and a minor risk of perforation in patients who have undergone complete resection compared with those who have residual disease.31,58-61
Standard-dose chemotherapy

EATL.54,55 Moreover, data from comparative genomic hybridization studies on tumor DNA suggest that chromosomal gains of 1q and 5q and segmental amplification of 9q or deletion in 16q are associated with EATL.56,57 However, we do not routinely detect these findings in patients with EATL.

Treatment
A validated standard treatment of EATL in patients with CD is still lacking. The low incidence of this malignancy, the wide spectrum of its clinical presentation, its complex diagnosis, and the frequently poor performance status of the host because of malnutrition hamper the development of prospective controlled or randomized clinical trials.
Surgery

The therapeutic role of surgery lies in local debulking and in resection of tumor masses with a high risk of obstruction or
Table 2. Results of the treatment with standard-dose chemotherapy

Most of the reports are retrospective, monocentric, and with treatment schedules that have changed over time. The estimated median survival is 7.5 months, whatever the stage of the lymphoma at onset.16,31,58,62-64 Standard-dose multidrug chemotherapy is the treatment most widely used in clinical practice for EATL. However, after the diagnosis has been ascertained, chemotherapy cannot be administered in more than 50% of cases because of low performance status, mainly due to preexisting unresponsive CD, lymphoma dissemination, and frequently advanced age; moreover, a further 50% of those patients who begin chemotherapy are not able to complete it because of complications or disease relapse or iatrogenic toxicity. No more than 35% to 40% of the patients who complete chemotherapy achieve complete remission of the lymphoma16,31,58,63; the overall response rate ranges from 40% to 60%, with a slight and hardly valuable advantage for patients with early-stage lymphoma compared with those with advanced stage disease. The median duration of complete remissions is nearly 6 months,16,64 without any statistically significant difference between clinical stages. The only exception is represented by the 28 cases with EATL of the German Group,63 which showed a median remission duration of 28 months (range, 17-39 months) and a median 2-year survival of 28% (range, 13%-43%) with a clear, though statistically not significant, difference between stages. The CHOP chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) is the one most widely used and generally responsible for an overall 5-year survival of 9% to 22%.16,31,62-64 Many other chemotherapy regimens have been used instead of CHOP (Table 2), such as BACOP (bleomycin, doxorubicin, cyclophosphamide, vincristine, and prednisone),62 ProMACEMOPP (prednisone, doxorubicin, cyclophosphamide, etoposide, mechlorethamine, vincristine, and procarbazine),62 VAMP (vincristine, doxorubicin, high-dose methotrexate, and prednisolone),16 PEACE-BOM (prednisolone, etoposide, doxorubicin, cyclophosphamide-bleomycin, vincristine, and methotrexate),16 and CHOEP

Study type Retrospective Retrospective Retrospective Retrospective Retrospective Prospective Prospective

Reference No. of patients No. operated No. chemotherapy-treated 62 16 61 31 64 58 63 24 31 1 10 54 23 10 12 25 1 7 49 13 10 11 24 1 10 31 15 10

Type of chemotherapy CHOP, BACOP, ProMACE-MOPP CHOP, VAMP, PEACE-BOM Hyper-CVAD CHOP CHOP, CHOP-like CHOP CHOEP

Overall response (complete response), % NG (NG) 58 (32) 100 (100) NG (50) 32 (32) NG (35) 60 (30)

Median survival, mo (range) 10 (0-196) 7.5 (0-83) 34 5 (1-12) 7 (0-140) 7 (NG) 7 (2-16)

BACOP indicates bleomycin, doxorubicin, cyclophosphamide, vincristine, prednisone; C, complete response; CHOP, cyclophosphamide, doxorubicin, vincristine, prenisone; CHOEP, same drugs as in CHOP plus etoposide; CT, chemotherapy; Hyper-CVAD: cyclophosphamide, vincristine, dexamethasone, methotrexate, cytarabine; NG, not given; O, overall response; PEACE-BOM, prednisolone, etoposide, doxorubicin, cyclophosphamide-bleomycin, vincristine, methotrexate; ProMACE-MOPP, prednisone, doxorubicin, cyclophosphamide, etoposide, mechlorethamine, vincristine, procarbazine; and VAMP, vincristine, doxorubicin, high-dose methotrexate, prednisolone.

From www.bloodjournal.org by guest on March 10, 2015. For personal use only.
2464 DI SABATINO et al BLOOD, 15 MARCH 2012 VOLUME 119, NUMBER 11

Table 3. Results of the treatment with high-dose chemotherapy followed by stem cell transplantation
Study type Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Prospective Prospective Prospective Reference 16 69 72 70 66 71 68 65 74 73 67 64 75 (RCD) No. transplanted 2 1 2 1 6 1 4 5 1 2 5 14 13 No. evaluable 2 1 2 1 6 1 4 5 1 0 0 14 13 Debulking chemotherapy PEACE-BOM EPOCH-ICE CHOP, MACOP-B CHOP-ESHAP IVE-HDMTX CHOP CHOP CHOP CHOP PACEB-IVAM-HAM CHOP DACMEMP (or PAEM) CHOP-IVE/MTX Conditioning treatment BEAM MPH-FARA BEAM, BEAM-like MCVC BEAM BEAM BEAM or MPH-FARA BEAM, BEAM-like BEAM BEAM TBI TBI HDCTX HDMPH or BEAM Complete response 2 1 NG 0 5 1 1 NG 1 1 NG 10 5 Median survival, mo (range) 31 (2-64) 11 NG 8 40 (3-52) 18 8 (2-34) 2 (0.5-14) 24 NG NG 60% at 5 y (1-140 ) MPH-FARA 66% at 4 y (10-67) EPOCH-ICE indicates etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, ifosfamide, carboplatin, and etoposide; MPH-FARA, melphalan and fludarabine; MACOP-B, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin; NG, not given; ESHAP, etoposide, methylprednisolone, cytarabine, and cisplatin; MCVC, ranimustine, carboplatin, etoposide, and cyclophosphamide; IVE-HDMTX, ifosfamide, etoposide, epirubicin, and high-dose methotrexate; PACEB, doxorubicin, cyclophosphamide, etoposide, bleomycin, vincristine, and prednisone; IVAM, ifosfamide, etoposide, cytosine arabinoside, and methotrexate; HAM, cytarabine and mitoxantrone; DACMEMP, dexamethasone, cytarabine, carmustine, etoposide, methylprednisolone, and cisplatin; PAEM, cisplatin, cytarabine, etoposide, and methylprednisolone; TBI, total body irradiation; HDCTX, high-dose cyclophosphamide; and HDMPH, high-dose melphalan.

(CHOP plus etoposide).63 All these regimens share 2 to 4 cornerstone drugs present in the CHOP schedule, with proven activity in lymphoproliferative diseases, and their efficacy proves similarly disappointing, with heavier toxicity if dose intensity is increased (BACOP) or other drugs are included (ProMACE-MOPP, PEACE-BOM, and CHOEP). Very few longterm survivors have been reported: 5 patients from the series of Gale et al with survival from 49 to 219 months after CHOP,16 and 1 patient from Honemann et al with persisting complete remission ¨ 34 months after the end of the intensive Hyper-CVAD regimen (cyclophosphamide, vincristine, dexamethasone, methotrexate, and cytarabine).61 These long-term survivors, who often, but not always, present early-stage disease at diagnosis, suggest that a study of the prognostic factors of EATL might be suitable if a sufficiently high number of patients were available. In our experience, patients who fail their first-line CHOP have a very dismal fate with a second-line conventional chemotherapy. In the experience of Raderer et al,59 6 of 19 patients underwent new chemotherapy regimens because of progressive disease or relapse. The regimens used were ICE (ifosfamide, carboplatin, and etoposide) in 2 patients, FC (fludarabine and cyclophosphamide) in another 2 subjects, cladribine in one, and DHAP (dexamethasone, cytarabine, and cisplatin) in the last. Three subjects responded completely (2 to FC and one to ICE), and 2 of them were still alive at 7 and 64 months, respectively; 1 died of disease progression after 10 months. All 3 nonresponders died of perforation within 2 weeks from the start of the second-line therapy.
High-dose chemotherapy with ASCT

The poor results of conventional chemotherapy have stimulated investigation into the feasibility and efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). This therapeutic option cannot be proposed to the large majority of patients because of their poor general condition, unresponsiveness to debulking therapy, iatrogenic toxicity and/or complications, or too early relapse. The series with the relatively highest number of treated patients are those by Jantunen et al (5 patients; median survival, 2 months),65 Bishton and Haynes (6 patients; 4 alive and disease-free 2-4 years after treatment,

2 relapsed early),66 Reimer et al (5 patients with EATL, without any specific information, of 83 cases with different T-cell histology, 55 of whom were transplanted),67 and Al-Toma et al (4 patients; 1 had ongoing complete remission 32 months after transplantation, 3 died from relapse within a few months after transplantation).68 Table 3 summarizes all the information available in the literature, including case reports. CHOP was generally used as the first-line chemotherapy and BEAM (carmustine, etoposide, cytarabine, and methotrexate) as the conditioning regimen. A novel first-line chemotherapy, consisting of a single course of CHOP plus 6 cycles of alternating IVE (ifosfamide, epirubicin, etoposide) and MTX (intermediate-dose methotrexate), followed by either BEAM or high-dose melphalan with total body irradiation as conditioning regimens, was planned by Sieniawski et al and administered in 26 patients and compared with another 35 who underwent standard chemotherapy or surgery alone.64 The eligibility criteria were de novo onset of the EATL, age of 18 years or older, and estimated ability to tolerate high-dose treatment. The number of patients excluded from the enrollment was not specified, and only 14 of the 26 included in the study actually underwent ASCT. The study was not randomized, but the improvement of 5-year overall survival and progression-free survival was impressive (60% vs 22% and 52% vs 22%, respectively). A single report69 of prolonged complete remission of a refractory EATL after reduced-intensity unrelated cord blood transplantation offers new outlooks on the efficacy of conditioning procedures with lower toxicity and a probable graft-versus-lymphoma activity. On the whole, these studies suggest that those patients who can tolerate more intensive treatments may benefit. We think that high-dose chemotherapy followed by ASCT represents a true landmark in the evolving treatment of EATL, but we recommend a very strict selection of the eligible patients because of their intrinsic frailty.
Radiotherapy

The administration of radiotherapy is seldom adopted in the treatment of patients with EATL and is reported as an occasional and ancillary measure related to chemotherapy. In the series by Novakovic et al, 6 of the 11 patients who completed the chemotherapy courses (4 with complete remission, 2 with partial response)

From www.bloodjournal.org by guest on March 10, 2015. For personal use only.
BLOOD, 15 MARCH 2012 VOLUME 119, NUMBER 11 ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA 2465

Figure 5. Main therapeutic options (white areas), 5-year survival, and IEL or infiltrating lymphoma cell immunophenotype (black areas), along the lymphomagenic process leading from uncomplicated CD to EATL through RCD. Unlike RCD1 (RCD1), which can benefit from steroids, such as prednisone or budesonide, combined or not with immunomodulators, such as azathioprine (AZA), 6-mercaptopurine (6-MP), or tacrolimus, RCD2 (RCD2) is less likely to respond to the aforementioned drugs. Therapeutic options in RCD2 may include cladribrine, alemtuzumab (anti-CD52 antibody), or high-dose chemotherapy (high-chemo) followed by ASCT. Standard-chemo indicates standard-dose chemotherapy. Black arrowheads represent probable progression; and white arrowheads, uncertain progression.

were then treated with radiotherapy, and all achieved complete remission.31 In the study reported by Daum et al, none of the patients with EATL was able to receive radiotherapy after chemotherapy, as scheduled, because of progressive disease or complications.58
Novel treatments

An interesting new treatment is alemtuzumab, a monoclonal antibody that targets CD52 on normal and pathologic T lymphocytes. Gallamini et al treated 24 patients with different histologic types of T-cell lymphoma with a combination of CHOP and alemtuzumab.76 The only patient presenting an EATL responded completely, but no information was given about the duration of response. Soldini et al successfully treated a 73-year-old woman with a typical history of CD and subsequent EATL, administering

alemtuzumab in combination with gemcitabine; the patient relapsed one year after and achieved a second durable complete remission with the same combined therapy.77 On the other hand, a gastric EATL in a 72-year-old man, treated by Kircher et al with CHOP plus alemtuzumab, showed an initial promising clinical and radiologic response but then rapidly progressed with a lethal outcome.78 Alemtuzumab was given at 30 mg 3 times a week for 4 consecutive weeks combined with antiviral therapy. Interestingly, alemtuzumab can prevent the risk of developing an EATL in subjects with RCD, as documented by the complete clinical and pathologic recovery of a woman with a 2-year history of RCD.79 Another single experience, however, did not confirm such efficacy.80 The clinical activity of cladribine, a synthetic purine nucleoside with cytotoxic effects, holds promise in the field of RCD and

From www.bloodjournal.org by guest on March 10, 2015. For personal use only.
2466 DI SABATINO et al BLOOD, 15 MARCH 2012 VOLUME 119, NUMBER 11

EATL. Cladribine has been used more in RCD2. In this setting of patients, the pilot study by Al-Toma et al recorded 6 of 17 clinical responses, with histologic improvement in 10 of 17 after 1 course of therapy (0.1 mg/kg with a 2-hour infusion daily for 5 days).81 These results were confirmed by Tack et al in 32 patients with RCD2 because 18 of 37 responders had a clearly higher 5-year survival and a decrease transition into EATL compared with nonresponders.82 Patients unresponsive to cladribine can be rescued with high-dose chemotherapy and stem cell transplantation.75 No information is available on the use of cladribine in overt EATL apart from the report by Raderer et al regarding a patient with relapsed and unresponsive EATL.59 A complete response, stable 8 months after treatment, was achieved in a patient with EATL also by romidepsin as a single agent, a histone deacetylase inhibitor active in T-cell lymphoma, administered in a phase 2 study83 on different types of T-cell lymphomas. Finally, laboratory studies are ongoing on the activity in vitro and in mice of a fully humanized IL-15 specific antibody (AMG714)24 able to block the signaling pathway by which IL-15 transmits antiapoptotic signals to IELs. It is probable that an antibody like this, which specifically acts on one crucial step of the lymphomagenesis, may be the conclusive weapon against EATL if used in RCD with the aim of preventing the malignant transformation of IELs. Figure 5 summarizes the main therapeutic options we adopt in patients with EATL or RCD.

risk of malignant complications in asymptomatic celiac patients.92 Until these results are confirmed, we strongly recommend that all celiac patients must maintain a strict life-long GFD. In conclusion, EATL is a rare disease with a very poor outcome. Unexplained weight loss, abdominal pain, diarrhea, loss of albumin and blood, increased LDH, fever, and night sweating should alert physicians to this complication in patients with a history of CD or RCD. However, EATL may also be diagnosed in patients without a known history of CD. The suspicion of EATL should lead to an extensive diagnostic workup in which MR enteroclysis, combined with PET scan and histologic identification of lesions, represents the best options. The best current treatment choice is high-dose chemotherapy, preceded by surgical resection and followed by ASCT, although this procedure can only be applied to a strictly selected number of patients able to tolerate it. Further studies are needed to verify whether innovative therapies might be of help in treating or preventing EATL. Strict adherence to a GFD remains the best option to prevent EATL in patients with CD.

Acknowledgments
The authors thank Dr Vincenzo Villanacci for providing the histologic pictures shown in Figure 4, and the Associazione Italiana Celiachia for supporting them in the study of complicated celiac disease.

Prophylaxis: the role of a gluten-free diet
Adherence to a strict GFD is of paramount importance in reducing the risk of developing CD complications, and its protective effect was shown more than 20 years ago; in the past few years, many papers have addressed this issue, confirming its importance.84-91 However, on the basis of a reduced malignancy risk in asymptomatic celiac patients diagnosed because of familiarity compared with celiac patients diagnosed because of symptoms, it has recently been suggested that there is no evidence that a GFD further reduces the

Authorship
Contribution: A.D.S., F.B., P.G.G., and G.R.C. synthesized ideas and wrote the paper. Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: Gino R. Corazza, Clinica Medica I, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Universita di Pavia, Piazzale Golgi 5, 27100 Pavia, ` Italy; e-mail: gr.corazza@smatteo.pv.it.

References
1. Di Sabatino A, Corazza GR. Coeliac disease. Lancet. 2009;373(9785):1480-1493. 2. Biagi F, Corazza GR. Mortality in celiac disease. Nat Rev Gastroenterol Hepatol. 2010;7(3):158162. 3. Biagi F, Corazza GR. Defining “gluten refractory enteropathy.” Eur J Gastroenterol Hepatol. 2001; 13(5):561-565. 4. Malamut G, Cellier C. Is refractory celiac disease more severe in old Europe? Am J Gastroenterol. 2011;106(5):929-932. 5. West J. Celiac disease and its complications: a time traveller’s perspective. Gastroenterology. 2009;136(1):32-34. 6. Roshan B, Leffler DA, Jamma S, et al. The incidence and clinical spectrum of refractory celiac disease in a north American referral center. Am J Gastroenterol. 2011;106(5):923-928. 7. Malamut G, Afchain P, Verkarre V, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology. 2009;136(1):81-90. 8. Al-Toma A, Verbeek WH, Hadithi M, von Blomberg BM, Mulder CJ. Survival in refractory coeliac disease and enteropathy-associated Tcell lymphoma: retrospective evaluation of singlecentre experience. Gut. 2007;56(10):1373-1378. 9. Daum S, Ipczynski R, Schumann M, Wahnschaffe U, Zeitz M, Ullrich R. High rates of complications and substantial mortality in both types of refractory sprue. Eur J Gastroenterol Hepatol. 2009;21(1):66-70. 10. Verbeek WH, Van De Water JM, Al-Toma A, Oudejans JJ, Mulder CJ, Coupe VM. Incidence of ´ enteropathy-associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands. Scand J Gastroenterol. 2008; 43(11):1322-1328. 11. Shack LG, Wood HE, Kang JY, et al. Small intestinal cancer in England & Wales and Scotland: time trends in incidence, mortality and survival. Aliment Pharmacol Ther. 2006;23(9):1297-1306. 12. Rubio-Tapia A, Murray JA. Classification and management of refractory coeliac disease. Gut. 2010;59(4):547-557. 13. Smedby KE, Akerman M, Hildebrand H, Glimelius B, Ekbom A, Askling J. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathytype T cell lymphoma. Gut. 2005;54(1):54-59. 14. Green PH, Fleischauer AT, Bhagat G, Goyal R, Jabri B, Neugut AI. Risk of malignancy in patients with celiac disease. Am J Med. 2003;115(3):191195. 15. Rubio-Tapia A, Kelly DG, Lahr BD, Dogan A, Wu TT, Murray JA. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology. 2009;136(1):99-107. 16. Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000; 18(4):795-803. 17. Gough KR, Read AE, Naish JM. Intestinal reticulosis as a complication of idiopathic steatorrhoea. Gut. 1962;3:232-239. 18. Deleeuw RJ, Zettl A, Klinker E, et al. Wholegenome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology. 2007; 132(5):1902-1911. 19. Biagi F, Bianchi PI, Vattiato C, et al. Influence of HLA-DQ2 and DQ8 on severity in celiac disease. J Clin Gastroenterol. 2012;46(1):46-50. 20. Biagi F, Poggioli G, Mazzoni G, Corazza GR. Intestinal strictures. Lancet. 1998;352(9131):876. 21. Biagi F, Lorenzini P, Corazza GR. Literature review on the clinical relationship between ulcerative jejunoileitis, coeliac disease and enteropathy associated T cell lymphoma. Scand J Gastroenterol. 2000;35(8):785-790. 22. Mention JJ, Ben Ahmed M, Begue B, et al. Inter` leukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in

From www.bloodjournal.org by guest on March 10, 2015. For personal use only.
BLOOD, 15 MARCH 2012 VOLUME 119, NUMBER 11 ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA 2467

celiac disease. Gastroenterology. 2003;125(3): 730-745. 23. Di Sabatino A, Ciccocioppo R, Cupelli F, et al. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut. 2006;55(4):469-477. 24. Malamut G, El Machhour R, Montcuquet N, et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest. 2010; 120(6):2131-2143. 25. Domizio P, Owen RA, Shepherd NA, Talbot IC, Norton AJ. Primary lymphoma of the small intestine: a clinicopathological study of 119 cases. Am J Surg Pathol. 1993;17(5):429-442. 26. Hovenga S, de Graaf H, Joosten P, et al. Enteropathy-associated T-cell lymphoma presenting with eosinophilia. Neth J Med. 2003;61(1):25-27. 27. McBride OM, Skipworth RJ, Leitch D, Yalamarthi S. Cavitating mesenteric lymph node syndrome in association with coeliac disease and enteropathy associated T-cell lymphoma: a case report and review of the literature. Case Report Med. 2010;2010:478269. 28. Di Sabatino A, Rosado MM, Cazzola P, et al. Splenic hypofunction and the spectrum of autoimmune and malignant complications in celiac disease. Clin Gastroenterol Hepatol. 2006;4(2):179186. 29. Di Sabatino A, Carsetti R, Corazza GR. Postsplenectomy and hyposplenic state. Lancet. 2011;378(9785):86-97. 30. Rohatiner A, d’Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5(5):397400. 31. Novakovic BJ, Novakovic S, Frkovic-Grazio S. A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin’s lymphomas. Oncol Rep. 2006; 16(1):191-195. 32. Musshoff K. Clinical staging classification of nonHodgkin’s lymphomas. Strahlentherapie. 1977; 153(4):218-221. 33. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987-994. 34. Delabie J, Holte H, Vose JM, et al. Enteropathyassociated T-cell lymphoma: clinical and histological findings from the international peripheral Tcell lymphoma project. Blood. 2011;118(1):148155. 35. de Baaij LR, van de Water JM, Verbeek WH, et al. Enteropathy associated T-cell lymphoma: a clinical prognostic model to identify high risk patients. Gastroenterology. 2011;140(suppl 1):A151. 36. Leighton JA. The role of endoscopic imaging of the small bowel in clinical practice. Am J Gastroenterol. 2011;106(1):27-36. 37. Al-Toma A, Verbeek WH, Mulder CJ. The management of complicated celiac disease. Dig Dis. 2007;25(3):230-236. 38. Mallant M, Hadithi M, Al-Toma AB, et al. Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma. World J Gastroenterol. 2007;13(11): 1696-1700. 39. Hadithi M, Mallant M, Oudejans J, et al. 18F-FDG PET versus CT for the detection of enteropathyassociated T-cell lymphoma in refractory celiac disease. J Nucl Med. 2006;47(10):1622-1627. 40. Hoffmann M, Vogelsang H, Kletter K, Zettinig G, Chott A, Raderer M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. Gut. 2003;52(3):347-351. 41. Laird J, Leach M, Ballantyne S. The value of

small bowel magnetic resonance imaging in the management of enteropathy associated T-cell lymphoma. Br J Haematol. 2008;142(1):136-137. 42. Van Weyenberg SJ, Meijerink MR, Jacobs MA, van Kuijk C, Mulder CJ, van Waesberghe JH. MR enteroclysis in refractory celiac disease: proposal and validation of a severity scoring system. Radiology. 2011;259(1):151-161. 43. Daum S, Wahnschaffe U, Glasenapp R, et al. Capsule endoscopy in refractory celiac disease. Endoscopy. 2007;39(5):455-458. 44. Hadithi M, Al-Toma A, Oudejans J, van Bodegraven AA, Mulder CJ, Jacobs M. The value of double-balloon enteroscopy in patients with refractory celiac disease. Am J Gastroenterol. 2007;102(5):987-996. 45. Matsumoto T, Nakamura S, Esaki M, et al. Double-balloon endoscopy depicts diminutive small bowel lesions in gastrointestinal lymphoma. Dig Dis Sci. 2010;55(1):158-165. 46. de Bruin PC, Connolly CE, Oudejans JJ, et al. Enteropathy-associated T-cell lymphomas have a cytotoxic T-cell phenotype. Histopathology. 1997; 31(4):313-317. 47. Bagdi E, Diss TC, Munson P, Isaacson PG. Mucosal intra-epithelial lymphocytes in enteropathyassociated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population. Blood. 1999;94(1):260-264. 48. Verbeek WH, Goerres MS, von Blomberg BM, et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. Clin Immunol. 2008;126(1):48-56. 49. Murray A, Cuevas D, Jones B, Wright DH. Study of the immunohistochemistry and T-cell clonality of enteropathy associated T-cell lymphoma. Am J Pathol. 1995;146(2):509-519. 50. Isaacson PG, O’Connor NTG, Spencer J, et al. Malignant histiocytosis of the intestine: AT-cell lymphoma. Lancet. 1985;2(8457):688-691. 51. Daum S, Weiss D, Hummel M, et al. Frequency of clonal intraepithelial T lymphocyte proliferations in enteropathy-type intestinal T cell lymphoma, coeliac disease, and refractory sprue. Gut. 2001; 49(6):804-812. 52. Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. Lancet. 2000; 356(9225):203-208. 53. Patey-Mariaud D, Serre N, Cellier C, et al. Distinction between coeliac disease and refractory sprue: a simple immunohistochemical method. Histopathology. 2000;37(1):70-77. 54. Al-Toma A, Goerres MS, Meijer JW, Pena AS, ˜ Crusius JB, Mulder CJ. Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma. Clin Gastroenterol Hepatol. 2006;4(3):315-319. 55. Wolters VM, Verbeek WH, Zhernakova A, et al. The MYO9B gene is a strong risk factor for developing refractory celiac disease. Clin Gastroenterol Hepatol. 2007;5(12):1399-1405. 56. Zettl A, Ott G, Makulik A, et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol. 2002;161(5):1635-1645. 57. Baumgartner AK, Zettl A, Chott A, Ott G, ¨ Muller-Hermelink HK, Starostik P. High frequency ¨ of genetic aberrations in enteropathy-type T-cell lymphoma. Lab Invest. 2003;83(10):1509-1516. 58. Daum S, Ullrich R, Heise W, et al. Intestinal nonHodgkin’s lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal Non-Hodgkin’s Lymphoma. J Clin Oncol. 2003;21(14):2740-2746. 59. Raderer M, Troch M, Kiesewetter B, et al. Second line chemotherapy in patients with enteropathyassociated T cell lymphoma: a retrospective

single center analysis. Ann Hematol. 2012;91(1): 57-61. 60. Ferreri AJ, Zinzani PL, Govi S, Pileri SA. Enteropathy-associated T-cell lymphoma. Crit Rev Oncol Hematol. 2011;79(1):84-90. 61. Honemann D, Prince HM, Hicks RJ, Seymour JF. ¨ Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options. Ann Hematol. 2005;84(2):118-121. 62. Egan LJ, Walsh SV, Stevens FM, Connolly CE, Egan EL, McCarthy CF. Celiac-associated lymphoma: a single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol. 1995;21(2):123-129. 63. Wohrer S, Chott A, Drach J, et al. Chemotherapy ¨ with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Ann Oncol. 2004;15(11):16801683. 64. Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115(18):3664-3670. 65. Jantunen E, Juvonen E, Wiklund T, Putkonen M, Nousiainen T. High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma. Leuk Lymphoma. 2003;44(12):2163-2164. 66. Bishton MJ, Haynes AP. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br J Haematol. 2007;136(1):111-113. 67. Reimer P, Rudiger T, Geissinger E, et al. Autolo¨ gous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27(1):106-113. 68. Al-Toma A, Verbeek WH, Visser OJ, et al. Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. Dig Liver Dis. 2007;39(7):634-641. 69. Chonabayashi K, Kondo T, Tanaka Y, Ichinohe T, Ishikawa T, Uchiyama T. Sustained complete remission of refractory enteropathy-type T-cell lymphoma following reduced-intensity unrelated cord blood transplantation. Bone Marrow Transplant. 2007;40(9):905-906. 70. Okuda M, Nomura J, Tateno H, Kameoka J, Sasaki T. CD56 positive intestinal T-cell lymphoma: treatment with high dose chemotherapy and autologous peripheral stem cell transplantation. Intern Med. 2002;41(9):734-737. 71. Rongey C, Micallef I, Smyrk T, Murray J. Successful treatment of enteropathy-associated T cell lymphoma with autologous stem cell transplant. Dig Dis Sci. 2006;51(6):1082-1086. 72. Blystad AK, Enblad G, Kvalay S, et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T-cell lymphomas. Bone Marrow Transplant. 2001;27(7):711-716. 73. Prochazka V, Faber E, Raida L, et al. Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011;155(1):63-70. 74. Nava VE, Cohen P, Bishop M, Fowler D, Jaffe ES, Ozdemidi M. Enteropathy-type T-cell lymphoma after intestinal diffuse large B-cell lymphoma. Am J Surg Pathol. 2007;31(3):476-480. 75. Tack GJ, Wondergem MJ, Al-Toma A, et al. AutoSCT in refractory celiac disease type II patients unresponsive to cladribine therapy. Bone Marrow Transplant. 2011;46(6):840-846. 76. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab

From www.bloodjournal.org by guest on March 10, 2015. For personal use only.
2468 DI SABATINO et al BLOOD, 15 MARCH 2012 VOLUME 119, NUMBER 11

(Campath-1H) and CHOP chemotherapy as firstline treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110(7):2316-2323. 77. Soldini D, Mora O, Cavalli F, Zucca E, Mazzucchelli L. Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy-type T-cell lymphoma. Br J Haematol. 2008;142(3): 484-486. 78. Kircher SM, Gurbuxani S, Smith SM. CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review. J Gastrointest Cancer. 2007;38(1):59-62. 79. Vivas S, Ruiz de Morales JM, Ramos F, Suarez-Vilela D. Alemtuzumab for refractory ce´ liac disease in a patient at risk for enteropathyassociated T-cell lymphoma. N Engl J Med. 2006; 354(23):2514-2515. 80. Verbeek WHM, Mulder CJJ, Zweegman S. Alemtuzumab for refractory celiac disease. N Engl J Med. 2006;355(13):1396-1397. 81. Al-Toma A, Goerres MS, Meijer JW, et al. Cladrib-

ine therapy in refractory celiac disease with aberrant T cells. Clin Gastroenterol Hepatol. 2006; 4(11):1322-1327. 82. Tack GJ, Verbeek WH, Al-Toma A, et al. Evaluation of cladribine treatment in refractory celiac disease type II. World J Gastroenterol. 2011; 17(4):506-513. 83. Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral Tcell lymphoma. Blood. 2011;117(22):5827-5834. 84. Corrao G, Corazza GR, Bagnardi V, et al. Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet. 2001;358(9279): 356-361. 85. Holmes GK, Prior P, Lane MR, Pope D, Allan RN. Malignancy in coeliac disease: effect of a gluten free diet. Gut. 1989;30(3):333-338. 86. Collin P, Reunala T, Pukkala E, Laippala P, Keyrilainen O, Pasternack A. Coeliac disease: ¨ associated disorders and survival. Gut. 1994; 35(9):1215-1218. 87. Peters U, Askling J, Gridley G, Ekbom A, Linet M. Causes of death in patients with celiac disease in

a population-based Swedish cohort. Arch Intern Med. 2003;163(13):1566-1572. 88. Viljamaa M, Kaukinen K, Pukkala E, Hervonen K, Reunala T, Collin P. Malignancies and mortality in patients with coeliac disease and dermatitis herpetiformis: 30-year population-based study. Dig Liver Dis. 2006;38(6):374-380. 89. Silano M, Volta U, Vincenzi AD, Dessì M, Vincenzi MD. Effect of a gluten-free diet on the risk of enteropathy-associated T-cell lymphoma in celiac disease. Dig Dis Sci. 2008;53(4):972-976. 90. Olen O, Askling J, Ludvigsson JF, Hildebrand H, ´ Ekbom A, Smedby KE. Coeliac disease characteristics, compliance to a gluten free diet and risk of lymphoma by subtype. Dig Liver Dis. 2011; 43(11):862-868. 91. Rampertab SD, Forde KA, Green PH. Small bowel neoplasia in coeliac disease. Gut. 2003; 52(8):1211-1214. 92. Gao Y, Kristinsson SY, Goldin LR, Bjorkholm M, ¨ Caporaso NE, Landgren O. Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology. 2009;136(1):91-98.

From www.bloodjournal.org by guest on March 10, 2015. For personal use only.

2012 119: 2458-2468 doi:10.1182/blood-2011-10-385559 originally published online January 23, 2012

How I treat enteropathy-associated T-cell lymphoma
Antonio Di Sabatino, Federico Biagi, Paolo G. Gobbi and Gino R. Corazza

Updated information and services can be found at: http://www.bloodjournal.org/content/119/11/2458.full.html Articles on similar topics can be found in the following Blood collections Free Research Articles (3000 articles) How I Treat (148 articles) Lymphoid Neoplasia (1957 articles) Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.…...

Similar Documents

Premium Essay

How I Became a Feminist

...Margot Heraud College Writing 100-61T Due 10/09/2012 Subject: Feminism. The way I became who I am isn’t the usual way we become someone. My dad and uncle raised me in the middle of a French restaurant kitchen with no real feminine influence. I would spend my days off in the kitchen, mostly helping out, but it was also the place where I would do my homework after school, where my dad and I would pretend to fight with wood spoons. This kitchen was one of the most familiar places I had ever known but it was also where I would escape. My mother was dealing with illness at that time, until I was about 11 but life couldn’t stop; my friends at schools were mostly boys and, as I grew up, I was more familiar with soccer and kickboxing than classical dancing. Soccer in France is mostly for boys anyway and since there was no girls’ team, that’s where I ended up, and I loved it. I felt more familiar around boys because they weren’t complicated. I didn’t mind bruises or being sweaty or even fighting, it was what I was made of. Being a girl and girl’s values was totally foreign to me. Until that time where a teenager becomes a young woman, I tried to discover my real identity and what I believed in, which is when I started reading some feminist novels and related myself to them. I believe that feminism is not only a movement; it can also be a certain kind of identity. My country has always been known to be faithful to our equality values that funded our republic. Some actions has......

Words: 1507 - Pages: 7

Premium Essay

How I Learned Essay

...How I Learned Essay In the beginning I was debating on should I go to school or just stay at home, and just stick to playing the organ at church. Something in my head told me to go ahead to go back to school so I can further my education. Since I love to be on the computer all the time I decided to find something to do with computers. When I heard my brother and my friend came in the house talking about Brown Mackie College. I looked in the book and then that’s when I saw Information Technology I knew it would be something very interesting when I looked at the courses. The first day of class in Professional Development, the first thing I learned how to get out of my box. Because I have always been scared to get out of my box, I never got a chance to make any friends, or got to know most of my teachers in school. This class has helped me out a lot, because I have got a chance to get to know my fellow classmates and made new friends. Getting out of my box gave me confidence that I really need. Stepping out of my box has shown me that I can make friends on campus and off campus. Second, we talked about in class was “What exactly is Success in College”. Success in College to me is really a challenge for me. All because I was used to being at home, and just going to church, I didn’t think about going back to College. I have already succeeded because I had enough courage to go back to school and further my education. Here my keys to be Successful in College: 1. Showing up......

Words: 692 - Pages: 3

Free Essay

How We Treat the Animals We Eat

...How We Treat the Animals We Eat Angela M Groves DeVry University How We Treat the Animals We Eat Are the factory farms we buy our meat from treating animals humanely? Animal mistreatment is illegal and we can make a difference to put a stop to it. According to Ethical Farms “Some of the largest US factory farms refuse to uphold humane USDA and OSHA standards, having unsanitary, unhealthy conditions and animal rights violations. In 1958, the US government composed the Humane Slaughter Act that is not enforced” (Ethical Farms, 2010). There are 7 statutes in effect that comprise the Humane Slaughter Act. Included in these sections are Congress' statement that livestock must be slaughtered in a humane manner to prevent needless suffering, research methods on humane methods of slaughter, the non-applicability of these statutes to religious or ritual slaughter, and the investigation into the care of non-ambulatory livestock. There are farms that follow the Humane Slaughter Act in raising their livestock that we can purchase our food from, like Humane Farms for example. By aligning our consumerism with Restaurants and grocery store chains that purchase from humane farms we can make an impact. Also, supporting an Animal Rights group like The American Society for Prevention of Cruelty to Animals(ASPCA) or The People for the Ethical Treatment of Animals(PETA) can make a big difference. You can support them either monetarily or by volunteering your time in your local......

Words: 1820 - Pages: 8

Premium Essay

How I Changed for the Better

...How I Changed for the Better This is going to be a waste of time, I thought as I descended the gray stairs to the gym. My friends surrounded me, filling the air with jokes and laughter. We were headed to the gymnasium for a bullying seminar that would last two periods. 150 minutes. I am not one to question missing class for a school-organized event, but today I would be missing study hall. Unfinished homework hung over me like an unstable roof about to collapse. I had a biology test and a few ignored assignments from last night, and the good student inside me ached when I heard I would miss that free period. But it wasn't just the urgency of unfinished school work that made me reluctant to attend this assembly; the topic made me uneasy too. We were all a little on edge when we heard from our parents that some serious subjects would be discussed today, things that weren't discussed openly in teenagers' lives, things that rarely crossed our minds. A speaker was going to tell us the story of his son who committed suicide after being bullied. His name was John Halligan. I sat near the front with my friends. Mr. Halligan began by introducing us to his son, Ryan, showing us a slide show with photos of a dark-haired boy as a toddler, a child, and then a teen. We watched as he slowly transformed from a happy kid to a slightly awkward teenager. He had a strange smile – like a mask that hid his pain. Mr. Halligan began telling us about his family, mostly his son. He told us of......

Words: 801 - Pages: 4

Free Essay

How to Treat Ibs Using Hypnosis

...Assignment - Module 8 Word Count 2221 This essay will be describing the condition irritable bowel syndrome. I will also be discussing the possible uses of hypnosis in helping to treat the aspects of this condition. Irritable bowel syndrome (IBS) is a condition of the gut and it has been noted that it is a condition which affects about 1 in 10 people at some time. Statistically it has been recorded that it is more prevalent among people between the ages of 25 – 45 and females are more affected than males. However this condition can cause problems at any age to both sexes and ethnicity may be a factor to be considered. For example data for Pakistan shows that males between 16-30 have a higher rate of IBS. There are many symptoms that many IBS suffers endure such as: Feeling and being sick by vomiting Diarrhoea Constipation Pain in the abdomen Bloating/wind Feeling that you haven’t fully emptied all faeces from the rectum Stress and anxiety Depression to list a few. This condition causes great problems with the sufferer as it can destroy and disrupt their day to day life. Before a person with IBS and a hypnotherapist work together the IBS patient should have already seen a GP and consequently been diagnosed. An ethical hypnotherapist would need to know that all other, more serious conditions such as bowel cancer, have been ruled out and that the problem is IBS for a fact. The doctor should......

Words: 2225 - Pages: 9

Free Essay

How Should I Live

...How Should I Live? With each decision, we constantly ask ourselves, “Is this the right decision?” Sooner or later, we are all presented with the task to choose between what is right and what is easy. In one of my favorite novel series, Harry Potter, Albus Dumbledore says to Harry, “It is our choices, Harry, that show what we truly are, far more than our abilities.” (Rowling 1998, 219) This is true. Our decisions in life, our struggles, selections, and choices, are the bindings to our stories; ultimately holding together what makes us who we are, just as Dumbledore said. How should we live our lives? It is not a question that can be simply stated in a few words. One word out of the posed question is the main subject- “live”. What does it mean to truly live and what is the best way to do it? I think it is a mixture of many things. However, out of many lifestyles that involve moral behavior, I think the life of an altruist is an extremely honorable one, and it is one by which I want to model my life. In order to do good, one must know evil. So, what is evil? What makes good people do bad things? According to Philip Zimbardo, “evil consists in intentionally behaving in ways that harm, abuse, demean, dehumanize, or destroy innocent others -- or using one’s authority and systemic power to encourage or permit others to do so on your behalf” (Zimbardo 2007, 5). Throughout history, we have seen multiple examples of evil acts; from the Rwandan Genocide to Abu Ghraib to the......

Words: 2681 - Pages: 11

Premium Essay

How Do I Learn

...Title : How do I learn? “Live as if you were to die tomorrow. Learn as if you were to live forever” (Mahatma Gandhi 1869-1948). Throughout life humans go through learning process. Learning is defined as obtaining information or skills through observation, study or experience. There are different types of learning styles according to Kolb’s learning theory (Payne,E. and Whittaker. L, 2006). Each individual learns in a different way, simply because they perceive and execute information or experience in their own preferred style. Kolb (1984) describes that there are four learning styles which would be Converger, Diverger, Assimilator and Accommodator respectively. I see my-self best fit into Diverger and Accommodator learning styles. According to Kolb, a diverger learner is good at applying concrete experience and reflective observation. A diverger is able to view things from different perspectives and often learn through observation. They also tend to solve problems using imaginations and carries feeling oriented personality. Divergers prefer to be an observant rather than taking part in any situations or issues. Kolb says that divergers perform well in situation where it requires generating ideas such as brainstorming. They often influenced by others, enjoy working in a group, like to receive positive feedback, and prefer to learn via logical instructions. For example, I had an interesting learning curve during my past working experience as a software programmer. For......

Words: 539 - Pages: 3

Premium Essay

How I Wrote Jubilee

...An Analysis of “How I Wrote Jubilee” Margaret Walker’s essay “How I Wrote Jubilee” is an essay that summarizes the author’s vast research for the Novel Jubilee. Based on stories her great-grandmother portrayed as bedtime stories in her childhood, the novel itself depicts the life and times of a character named Vyry that went through slavery, the Civil War and reconstruction. This responsive essay gives way to an establishment of educated and factual data through timing, oral history of the stories of those who were in slavery, and primary research of the subject matter, thereby providing ample documentation of the credibility of her novel. When gauging whether an author’s writing is credible, one must first inquire what their educational background is. Keeping this in mind, there are several references of the educational background of Walker in the essay “How I Wrote Jubilee.” Graduating from Northwestern University in Iowa at the young age of 19, Walker went on to obtain her master’s in English from the University of Iowa in 1939, graduating in just a year in 1940. Here she studied at the Writer’s Workshop and began writing her thesis on the Civil War, compiling and reading a laundry list of books about the South, the Negro during slavery, and the slave codes in Georgia. Although Walker’s poem “For My People” was published in 1942 her father heeded warning by stating, “I would have to eat if I wanted to live, and writing poetry would not feed me (Walker 52).” It is......

Words: 1191 - Pages: 5

Premium Essay

How I Write

...How I Write Brandy Jolly Grantham University HOW I WRITE When I am confronted with a writing task, I ultimately freeze up. I do not know where to begin. While writing my paper I tend to write the same things over and over again. I used to sit down every night and write in a journal. Since have kids I do not have time to do that anymore. So over the years my writing has gotten really bad. When I do my writing assignments I have to have complete silence with no interruptions. I have found that I can concentrate on my assignment better at night after my kids go to sleep. I want to be able to write an essay or paper that makes sense and has proper punctuation and grammar by the time this course is over. My writing process includes a lot of free writing. What I am thinking is what I write on my paper. I believe that studying the APA guide will greatly improve my writing skills. The APA guide will give me complete details on how to set up my paper correctly. The EBSCO tutorial is very beneficial in that it allows me to learn how to research papers that will teach me how to write more efficiently. I can also use the list of FAQ to answer questions that I may have concerning my assignment. Most of all I will be using my instructor as well as my classmates to help me during this course....

Words: 253 - Pages: 2

Premium Essay

How I Learned to Swim

...Learning how to swim: a real challenge Learning something new can be a very unnerving experience. One of the hardest things I have ever had to do was learn how to swim. I have always been afraid of the water but I believe that swimming is a very important skill for one to develop either for essential or fun reasons. What ever the reason is, swimming is a good exercise and promotes discipline. What I didn’t realize was that learning how to swim would help me become more self-confident. Luckily, my swimming lessons were not a painful experience because my instructor was a person that I already knew: my girlfriend. She used to be a swimming instructor and I was present in a couple of sessions in the past with previous students she had. Therefore, I knew how she worked. Her smile and patience were motivating enough for any shy student that wished to learn how to swim. The first emotion I would have expected to feel was embarrassment for being a rookie in something that my own girlfriend was already an expert. However, this didn’t happen at all. In fact, I felt so excited because I was going to experience something new with a person I already knew. That means that I saw the bright side of things. Nevertheless, my biggest concern was that I had to face my biggest fear: the water. Floating was the very first thing I learned to do. She had me put on water wings on each arm until I was able to float. So half of my fear was gone as soon as I felt I......

Words: 488 - Pages: 2

Premium Essay

How I Learn

...There are many different ways people can learn. I think the way you have grown up influences the way we learn. There are 7 different learning styles, Visual: You prefer using pictures, images, and spatial understanding. Aural: You prefer using sound and music. Verbal: You prefer using words, both in speech and writing. Physical: You prefer using your body, hands and sense of touch. Logical: You prefer using logic, reasoning and systems. Social: You prefer to learn in groups or with other people. Solitary: You prefer to work alone and use self-study. But I don’t think you can put a person in just one learning style. For me I use several different styles solitary, logical and visual. I like to be alone, study and memorize. I’m very dependent on lists. I like using pictures, charts and diagrams to show relationships with the learning. With learning more about myself on how I learn. I think I can improve on my learning. Read stories, assignments out loud. I can create a personal interest in my topics. Make an association with what I’m studying to recall it better. When I make my list I can extract key points that I need to know. I think one thing I learned is the library. We have databases that give you a lot of resource that we can trust. Then just hitting the internet and hoping it’s correct. You can also email the Librarians, which is very cool. Read the syllabus. It’s a very critical resource, it’s like a road map for your class. Make......

Words: 374 - Pages: 2

Premium Essay

How Should You Treat People with Disabilities

...How should you treat people with disabilities? 1. Treat PWDs like you want to be treated. 2. Talk to PWDs directly instead of their personal attendants. 3. Ask a PWD first instead of automatically assuming in what the PWD wants or needs. 4. Do not stare. 5. Do not treat adult PWDs as children. 6. Do not call PWDs the terms "Special Needs Person" or "Special Person". The same way you would hope to be treated. And that is with DIGNITY & RESPECT at all times, always remember they are people first and foremost. They have the same rights as you or I, and that most are very capable of making choices and decisions for themselves. Be patient caring and understanding, always offer assistance, and wait for a reply, before trying to help, as I have seen many people given an ear full for not giving them the chance to do for themselves. What not to do Never make assumptions, especially about their intellectual abilities, as this is a sure way of being given a thorough dressing down. Don't pity them as this will give them cause to dislike you, they don't want pity. Don't treat them with disrespect or call them derogatory names, that refer to their disability or mental state, e.g retard etc, as this will offend them and anyone who maybe with them. Never take over anything they are trying to do, ask if they would like help, and back off if they no. I work with people with disabilities and have seen many people given a ear full......

Words: 782 - Pages: 4

Free Essay

How I Use Math

...How I use Math in everyday Life DeVry University Math-032 October 9, 2012 How I use Math in Everyday Life Math is everywhere you go. It is at the store when you go groceries shopping, when you go out for dinner, when you’re at work, and even when you’re asleep. We are always using some kind of fraction throughout the day. I deal with numbers just about everywhere I go. Math has always been on my vocabulary since I was young. Coming from a house of five, I deal with math every single day. I have to use math for my bills, the rent, groceries, gas, things that are important in the house. Now that I completed eleven and half years in the united Stated Marine Corps, I deal with a tremendous budget in my house. I know that things are not the same because I don’t have a steady income coming in I have to keep track of our expenses and cut back on a lot of unimportant expenses. No matter what we do whether it’s at work, home, or out in town, numbers will always be a factor. Math will be involved and that’s the good think about life. Most people need a solid understanding for financial success and math is the answer. (Huebsch, 2009) In life, you will always have that percent that only need to learn numbers to a certain point. We engage numbers at a very young age. No one really knows how long numbers have been around for. Most people understand the concept of numbers, equations, and the use of daily concepts. (Melayu, 2009) I could say that Im that percentage in......

Words: 520 - Pages: 3

Premium Essay

How I Learned to Drive

...3/20/15 How I Learned to Drive After completing the play “How I Learned to Drive” I couldn’t help myself but to try and put all the pieces together. There were so many messages that weren’t clear and the listeners really needed to take advantage of their critical thinking skills. This play’s style is epic theatre, this means that there is a lesson to be learned within the play. In the play they try and teach the lesson as if you are learning to drive a car. There are many different gears in a car, just like there are many different gears in your life. We have our childhood gear, this is where we learn the basics of life like what is right or wrong. We have our teenage gear, this is when we learn how to adapt into the real world and learn the knowledge to succeed. Next, we have our adult gear, this is where you take everything you learned and make a life for yourself. Lastly, we have our teaching gear, this is when we take everything we learned in life and we are able to teach and mentor our family. It all comes full circle just like how the student becomes the teacher. In our mind’s it is very simple everything comes in chronological order. Unfortunately, this does not always happen this way. This play was the perfect representation of that. Growing up Lil Bit was finding her life to at a rapid pace. Her body was maturing quickly and so was the interest in her by people of the opposite sex. Lil Bit was always feeling targeted while she was growing up since she has always......

Words: 741 - Pages: 3

Free Essay

How to Treat Mad People

...probably natural Dresses: Traditional Japanese clothing distinguishes Japan from all other countries around the world. The Japanese word kimono means "something one wears" and they are the traditional garments of Japan. Formal kimonos are typically worn in several layers, with number of layers, visibility of layers, sleeve length, and choice of pattern dictated by social status, season, and the occasion for which the kimono is worn. Because of the mass availability, most Japanese people wear western style clothing in their everyday life, and kimonos are mostly worn for festivals, and special events. As a result, most young women in Japan are not able to put the kimono on themselves. Many older women offer classes to teach these young women how to don the traditional clothing. Happi is another type of traditional clothing, but it is not famous worldwide like the kimono. A happi (or happy coat) is a straight sleeved coat that is typically imprinted with the family crest, and was a common coat for firefighters to wear. Japan also has very distinct footwear. Tabi, an ankle high sock, is often worn with the kimono. Tabi are designed to be worn with geta a type of thonged footwear. Geta are sandals mounted on wooden blocks held to the foot by a piece of fabric that slides between the toes. Geta are worn both by men and women with the kimono Sports Baseball, football, and other popular western Sports were imported to Japan in the Meiji period. These sports are commonly......

Words: 2213 - Pages: 9